Smad3-mediated signals showing similarities and differences between epithelial and mesenchymal cells in human chronic liver diseases

Current Enzyme Inhibition

Volumn 6, Issue 2, 2010, Pages 57-66

  Matsuzaki, Koichi ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; C jun n terminal kinase; Review; Smad; Transforming growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN FIBER; INTERLEUKIN 1BETA; PLATELET DERIVED GROWTH FACTOR; SCLEROPROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ARTICLE; CELL FUNCTION; CHRONIC LIVER DISEASE; CLINICAL FEATURE; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS C; HUMAN; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; LIVER CELL; LIVER FIBROSIS; MESENCHYME CELL; NONHUMAN; PORTAL VEIN; PROTEIN PHOSPHORYLATION;

EID: 82155194840     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/157340810791233006     Document Type: Article

References (61)

1. Friedman, S.L. Liver fibrosis-from bench to bedside. J. Hepatol., 2003, 38, S38-S53.
2. Gines, P.; Cardenas, A.; Arroyo, V.; Rodes, J. Management of cirrhosis and ascites. N. Engl. J. Med., 2004, 350, 1646-1654.
3. Poynard, T.; Bedossa, P.; Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997, 349, 825-832.
4. Berenguer, M.; Prieto, M.; Palau, A.; Rayon, J.M.; Carrasco, D.; Juan, F.S.; Lopez-Labrador, F.X.; Moreno, R.; Mir, J.; Berenguer, J. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl., 2003, 9, 228-235.
5. Bataller, B.; Brenner, D.A. Liver fibrosis. J. Clin. Invest., 2005, 115, 209-218.
6. Pinzani, M. Liver fibrosis. Springer Semin. Immunopathol., 1999, 21, 475-490.
7. Benyon, R.C.; Iredale, J.P. Is liver fibrosis reversible? Gut, 2000, 46, 443-446.
8. Arthur, M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279, G245-G249.
9. Tahashi, Y.; Matsuzaki, K.; Date, M.; Yoshida, K.; Furukawa, F.; Sugano, Y.; Matsushita, M.; Himeno, Y.; Inagaki, Y.; Inoue, K. Differential regulation of TGF-β signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology, 2002, 35, 49-61.
10. Hu, P.F.; Chen, H.; Zhong, W.; Lin, Y.; Zhang, X.; Chen, Y.X.; Xie, W.F. Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J. Hepatol., 2009, 51, 102-113.
11. Eitzman, D.T.; McCoy, R.D.; Zheng, X.; Fay, W.P.; Shen, T.; Ginsburg, D.; Simon, R.H. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest., 1996, 97, 232-237.
12. Kmiec Z. Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol., 2001, 161, 1-151.
13. Higuchi, H.; Gores, G.J. Mechanisms of liver injury: an overview. Curr. Mol. Med., 2003, 3, 483-490.
14. Canbay, A.; Friedman, S.; Gores, G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology, 2004, 39, 273-278.
15. Casini, A.; Ceni, E.; Salzano, R.; Biondi, P.; Parola, M.; Galli, A.; Foschi, M.; Caligiuri, A.; Pinzani, M.; Surrenti, C. Neutrophilderived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology, 1997, 25, 361-367.
16. Friedman, S.L.; Roll, F.J.; Boyles, J.; Bissell, D.M. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc. Natl. Acad. Sci. USA, 1985, 82, 8681-8685.
17. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis., 2001, 21, 311-335.
18. Friedman, S.L.; Rockey, D.C.; McGuire, R.F.; Maher, J.J.; Boyles, J.K.; Yamasaki, G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology, 1992, 15, 234-243.
19. Rockey, D.C.; Housset, C.N.; Friedman, S.L. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J. Clin. Invest., 1993, 92, 1795-1804.
20. Kawada N. The hepatic perisinusoidal stellate cell. Histol. Histopathol., 1997, 12, 1069-1080.
21. Ramadori, G.; Saile, B. Portal tract fibrogenesis in the liver. Lab. Invest., 2004, 84, 153-159.
22. Kalluri, R.; Neilson, EG. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest., 2003, 112, 1776-1784.
23. Heldin, C.H.; Landstrom, M.; Moustakas, A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol., 2009, 21, 166-176.
24. Weng, H.L.; Ciuclan, L.; Liu, Y.; Hamzavi, J.; Godoy, P.; Gaitantzi, H.; Kanzler, S.; Heuchel, R.; Ueberham, U.; Gebhardt, R.; Breitkopf, K.; Dooley, S. Profibrogenic transforming growth factor-β /activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology, 2007, 46, 1257-1270.
25. Marra, F. Chemokines in liver inflammation and fibrosis. Front. Biosci., 2002, 7, d1899-1914.
26. Bissell, D.M.; Roulot, D.; George, J. Transforming growth factorβ and the liver. Hepatology, 2001, 34, 859-867.
27. Kolb, M.; Margetts, P.J.; Anthony, D.C.; Pitossi, F.; Gauldie, J. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest., 2001, 107, 1529-1536.
28. Burns, K.D. Interleukin-1β as a mediator of tubulointerstitial fibrosis. Kidney Int., 2002, 62, 346-347.
29. Gasse, P.; Mary, C.; Guenon, I.; Noulin, N.; Charron, S.; Schnyder- Candrian, S.; Schnyder, B.; Akira, S.; Quesniaux, V.F.; Lagente, V.; Ryffel, B.; Couillin, I. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest., 2007, 117, 3786-3799.
30. Pinzani, M.; Gesualdo, L.; Sabbah, G.M.; Abboud, H.E. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Invest., 1989, 84, 1786-1793.
31. Borkham-Kamphorst, E.; Stoll, D.; Gressner, A.M.; Weiskirchen, R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem. Biophys. Res. Commun., 2004, 321, 413-423.
32. Sporn, M.B.; Roberts, A.B. Peptide growth factors are multifunctional. Nature, 1988, 332, 217-219.
33. Massagué, J. TGF-β signal transduction. Annu. Rev. Biochem., 1998, 67, 753-791.
34. Heldin, C.H.; Miyazono, K.; Dijke, P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature, 1997, 390, 465-471.
35. Attisano, L.; Wrana, J.L. Signal transduction by the TGF-β superfamily. Science, 2002, 296, 1646-1647.
36. Kretzschmar, M.; Doody, J.; Timokhina, I.; Massagué, J. A mechanism of repression of TGF-β/ Smad signaling by oncogenic Ras. Genes Dev., 1999, 13, 804-816.
37. Mori, S.; Matsuzaki, K.; Yoshida, K.; Furukawa, F.; Tahashi, Y.; Yamagata, H, Sekimoto, G.; Fujisawa, J.; Okazaki, K. TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene, 2004, 23, 7416-7429.
38. Furukawa, F.; Matsuzaki, K.; Mori, S.; Tahashi, Y.; Yoshida, K.; Sugano, Y.; Yamagata, H.; Matsushita, M.; Seki, T.; Inagaki, Y.; Nishizawa, M.; Fujisawa, J.; Inoue, K. f signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology, 2003, 38, 879-889.
39. Matsuura, I.; Denissova, NG.; Wang, G.; He, D.; Long, J.; Liu, F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature, 2004, 430, 226-231.
40. Millet, C.; Yamashita, M.; Heller, M.; Yu, L.R.; Veenstra, T.D.; Zhang, Y.E. A negative feedback control of transforming growth factor-β signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J. Biol. Chem., 2009, 284, 19808-19816.
41. Matsuzaki, K. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis. Histol. Histopathol., 2006, 21, 645-662.
42. Derynck, R.; Zhang, Y.; Feng, X.H. Smads: transcriptional activators of TGF-β responses. Cell, 1998, 95, 737-740.
43. Sekimoto, G.; Matsuzaki, K.; Yoshida, K.; Mori, S.; Murata, M.; Seki, T.; Matsui, H.; Fujisawa, J.; Okazaki, K. Reversible Smaddependent signaling between tumor suppression and oncogenesis. Cancer Res, 2007, 67, 5090-5096.
44. Matsuzaki, K.; Kitano, C.; Murata, M.; Sekimoto, G.; Yoshida, K.; Uemura, Y.; Seki, T.; Taketani, S.; Fujisawa, J.; Okazaki, K. Smad2 and Smad3 phosphorylated at both linker and COOHterminal regions transmit malignant TGF-β signal in later stages of human colorectal cancer. Cancer Res, 2009, 69, 5321-5330.
45. Yoshida, K.; Matsuzaki, K.; Mori, S.; Tahashi, Y.; Yamagata, H.; Furukawa, F.; Seki, T.; Nishizawa, M.; Fujisawa, J.; Okazaki, K. Transforming growth factor-β and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am. J. Pathol., 2005, 166, 1029-1039.
46. Moustakas, A.; Kardassis, D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl. Acad. Sci. USA, 1998, 95, 6733-6738.
47. Yang, Y.A.; Zhang, G.M.; Feigenbaum, L.; Zhang, Y.E. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell, 2006, 9, 445-457.
48. Yamagata, H.; Matsuzaki, K.; Mori, S.; Yoshida, K.; Tahashi, Y.; Furukawa, F.; Sekimoto, G.; Watanabe, T.; Uemura, Y.; Sakaida, N.; Yoshioka, K.; Kamiyama, Y.; Seki, T.; Okazaki, K. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)- terminal kinase during human colorectal carcinogenesis. Cancer Res., 2005, 65, 157-165.
49. Matsuzaki, K.; Murata, M.; Yoshida, K.; Sekimoto, G.; Uemura, Y.; Sakaida, N.; Kaibori, M.; Kamiyama, Y.; Nishizawa, M.; Fujisawa, J.; Okazaki, K.; Seki, T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factorβ signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology, 2007, 46, 48-57.
50. Murata, M.; Matsuzaki, K.; Yoshida, K.; Sekimoto, G.; Tahashi, Y.; Mori, S.; Uemura, Y.; Sakaida, N.; Fujisawa, J.; Seki, T.; Kobayashi, K.; Yokote, K.; Koike, K.; Okazaki, K. Hepatitis B virus X protein shifts human hepatic TGF-β signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology, 2009, 49, 1203-1217.
51. Bonniaud, P.; Margetts, P.J.; Ask, K.; Flanders, K.; Gauldie, J.; Kolb, M. TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis. J. Immunol., 2005, 175, 5390-5395.
52. Wrighton, K.H.; Lin, X.; Feng, X.H. Phospho-control of TGF-β superfamily signaling. Cell Res., 2009, 19, 8-20.
53. Guo, X.; Wang, X.F. Signaling cross-talk between TGF-β /BMP and other pathways. Cell Res., 2009, 19, 71-88.
54. Inagaki, Y.; Okazaki, I. Emerging insights into Transforming growth factor β Smad signal in hepatic fibrogenesis. Gut, 2007, 56, 284-292.
55. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol., 2009, 27, 519-550.
56. McGuinness, P.H.; Painter, D.; Davies, S.; McCaughan, G.W. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 2000, 46, 260-269.
57. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature, 2003, 425, 577-584.
58. Saika, S.; Kono-Saika, S.; Ohnishi, Y.; Sato, M.; Muragaki, Y.; Ooshima, A.; Flanders, K.C.; Yoo, J.; Anzano, M.; Liu, C.Y.; Kao, W.W.; Roberts, A.B. Smad3 signaling is required for epithelialmesenchymal transition of lens epithelium after injury. Am. J. Pathol., 2004, 164, 651-663.
59. Dooley, S.; Hamzavi, J.; Ciuclan, L.; Godoy, P.; Ilkavets, I.; Ehnert, S.; Ueberham, E.; Gebhardt, R.; Kanzler, S.; Geier, A.; Breitkopf, K.; Weng, H.; Mertens, P.R. Hepatocyte-specific Smad7 expression attenuates TGF-β-mediated fibrogenesis and protects against liver damage. Gastroenterology, 2008, 135, 642-659.
60. Nagata, H.; Hatano, E.; Tada, M.; Murata, M.; Kitamura, K.; Asechi, H.; Narita, M.; Yanagida, A.; Tamaki, N.; Yagi, S.; Ikai, I.; Matsuzaki, K.; Uemoto, S. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology, 2009, 49, 1944-1953.
61. Arthur, M.J. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology, 2002, 122, 1525-1528.